LL-37 · Research brief
LL-37 Dosage and Antimicrobial Research: 2026 Evidence Overview
Short answer
Direct answer: there is no established "best" LL-37 dosage for antimicrobial purposes in 2026, and this page is not a protocol guide. LL-37 — the mature antimicrobial fragment of the only human cathelicidin — is handled as a research-grade material for laboratory use only and is not for human consumption.
Key takeaways
- LL-37 antimicrobial activity is described as concentration-dependent and biphasic: membrane disruption and immune signalling in lower assay bands, host cytotoxicity and inflammatory signalling as concentrations rise. Escalation is not a neutral variable in study design.
- The mechanism is physical membrane disruption plus FPR2-associated immune signalling, which is a different target class from enzyme-inhibiting antibiotics. Bacterial countermeasures to cationic peptides are nonetheless described in the literature.
- Human interventional data on exogenously supplied LL-37 is thin. The antimicrobial, biofilm, and wound findings discussed here come predominantly from in vitro and animal models, and are labelled as such.
- Peptide integrity — solution age, temperature history, light exposure, freeze-thaw cycling — is a documented confounder in peptide assay work generally, and a clear-looking solution is not evidence of intact peptide.
- No validated amount, frequency, duration, or administration route for antimicrobial use in humans is specified in the literature referenced on this page, and none is supplied here.
Direct answer: there is no established "best" LL-37 dosage for antimicrobial purposes in 2026, and this page is not a protocol guide. LL-37 — the mature antimicrobial fragment of the only human cathelicidin — is handled as a research-grade material for laboratory use only and is not for human consumption. The published record on LL-37 is dominated by in vitro and animal work, where activity is expressed as a concentration in an assay system (µg/mL or µM) rather than as a milligram amount given to a person on a schedule. The literature does not specify a validated human amount, frequency, or duration for antimicrobial use, and nothing here describes how to prepare or administer the peptide.
For anyone searching for an LL-37 antimicrobial research protocol, the honest position is the same: study designs vary by model, and there is no single standardised laboratory method that the field treats as canonical. What the record does describe is a concentration-dependent, biphasic molecule — membrane-disrupting and chemotactic in the lower concentration bands used in culture, increasingly cytotoxic to mammalian cells and pro-inflammatory as concentrations rise. Human clinical evidence for exogenously supplied LL-37 is thin; the bulk of the antimicrobial and wound-related findings come from preclinical systems, and that distinction is carried through every section below.
A note on sourcing. This page carries no PubMed-indexed citations. Because of that, it does not restate effect sizes, percentages, timelines, or trial outcomes attributed to any specific study, review, or journal. Where mechanism is described, it reflects general descriptions of cathelicidin and peptide biology and is labelled as mechanistic reasoning rather than a compound-specific trial result. Where a figure would be needed — a stability window, a threshold concentration, a bioavailability percentage — this page states that the literature referenced here does not specify it rather than supplying a number.
Most popular write-ups present LL-37 as a straightforward antimicrobial that is escalated until symptoms resolve. That framing conflicts with how the peptide behaves in laboratory systems, where the same molecule that permeabilises bacterial membranes at one concentration band acts as an immune signalling ligand at another and as a cytotoxic, inflammation-amplifying agent at higher ones. The sections below cover what antimicrobial research has actually measured, which model types produced those observations, how peptide stability variables are described in laboratory settings, and where the evidence remains open.
LL-37 Antimicrobial Mechanism and Concentration-Dependent Behaviour
LL-37 is a short, cationic, amphipathic peptide released by proteolytic processing of the hCAP18 precursor. Its antibacterial action is described mechanistically as a physical one: the positively charged face of the helix is drawn electrostatically to the anionic surfaces characteristic of bacterial membranes, the peptide partitions into the lipid bilayer, and bilayer integrity is lost. Because this is membrane-level damage rather than inhibition of a single enzyme target, the mechanism is not the same class of target that classical efflux-pump or beta-lactamase resistance is built around. That is a mechanistic argument, not a claim that resistance to LL-37 cannot arise — bacterial countermeasures such as surface charge modification and secreted proteases are also described in the peptide literature.
The second described role is immunomodulatory. LL-37 is characterised as a ligand at formyl peptide receptor 2 (FPR2) and as an influence on chemotaxis of neutrophils and monocytes, on epithelial signalling, and on the handling of bacterial products such as LPS. This host-directed activity is part of why cathelicidin biology is discussed in innate immunity research at all, and it is also why the molecule is not a straight analogue of a conventional antibiotic: part of its described activity runs through host cells rather than through the pathogen alone.
The concentration dependence is the part that is most often flattened in consumer-facing summaries. In culture systems, the concentration band that permeabilises bacterial membranes and the band that becomes cytotoxic to host cells are not far apart, and higher concentrations are associated in preclinical work with inflammatory signalling rather than with cleaner bacterial clearance. The practical consequence for study design is that "more peptide" is not a neutral variable in an assay. The specific numeric thresholds at which this inversion occurs are assay- and model-dependent, and the literature referenced on this page does not specify a single threshold — still less a milligram equivalent for a living subject.
What Antimicrobial Research Contexts Have Examined
Innate immune defence is the oldest context. Much of this work is observational rather than interventional: it measures endogenous cathelicidin expression in epithelial surfaces, neutrophil granules, and secretions, and correlates expression with infection susceptibility. This body of work describes what the host produces and when. It does not describe an exogenous administration schedule, and reading it as though it did is the most common category error in peptide write-ups.
Acute bacterial challenge work is largely in vitro and animal. Endpoints include minimum inhibitory concentration determinations against Gram-positive and Gram-negative isolates, time-kill kinetics, and bacterial burden in animal wound or infection models. Membrane-targeting peptides are studied specifically because their activity has been reported against isolates that resist conventional drug classes; that is a research rationale, not an outcome that can be promised for any reader.
Biofilm work is a distinct context because a biofilm is a different physical problem from planktonic bacteria. Studies here measure matrix penetration, adhesion and biofilm formation at sub-inhibitory concentrations, and the density or viability of established biofilms. Results in biofilm models do not transfer automatically to planktonic assays or to animal infection models, and the literature referenced here does not specify a concentration band that performs consistently across all three.
Wound repair overlaps with, but is not identical to, antimicrobial work. Cathelicidin is discussed in re-epithelialisation, angiogenesis, and the recruitment of immune cells to a wound bed. Because the same molecule is both antimicrobial and inflammation-modulating, wound models are where the biphasic character shows up most visibly in the preclinical record.
Adjunct and combination contexts — peptide alongside a conventional antibiotic — are studied mainly as checkerboard or synergy assays in vitro. These measure whether the combination lowers the effective concentration of one or both agents. Human data on exogenous LL-37 as an adjunct is thin, and that gap is a statement about the evidence, not a hidden recommendation.
Stability and Handling Variables Described in Laboratory Settings
Peptide integrity is a recognised confounder in antimicrobial assay work, and it is worth describing at the level of general peptide science because that is where the reliable description sits. Lyophilised peptide material is generally more stable than peptide in aqueous solution. Once in solution, the degradation pathways commonly described for peptides include hydrolysis, oxidation of susceptible residues, aggregation, and adsorption onto container surfaces — all of which reduce the concentration of intact, active peptide without necessarily changing how the solution looks.
That last point matters for interpreting a negative result. Visual clarity is not an assay. A solution that has lost structural integrity can remain clear while bioassay activity falls, which is why laboratory work that reports antimicrobial endpoints typically controls storage temperature, light exposure, freeze-thaw cycling, and time-in-solution as explicit variables rather than as background assumptions.
Compound-specific stability figures for LL-37 — a defined in-solution shelf life, a permissible temperature excursion window, a percentage of activity lost per freeze-thaw cycle — are not specified in the literature referenced on this page, and no figures are supplied here in their place. Manufacturer certificates of analysis and primary stability studies are the appropriate sources for those parameters. Real Peptides supplies LL-37 as research-grade material intended for laboratory research, and the same handling caveats that apply to any peptide in the full peptide collection apply to it: documented storage conditions are part of the experimental record, not an afterthought.
Route is likewise a study-design variable rather than an instruction. Peptides of this size and composition are generally described as poorly suited to oral delivery because of proteolytic degradation in the gastrointestinal tract, which is why preclinical antimicrobial work typically uses topical, local, or parenteral delivery in animal models. A specific bioavailability percentage for LL-37 by any route is not specified in the literature referenced here.
LL-37 Antimicrobial Research Contexts: Evidence Snapshot
| Research Context | Predominant Model Type | What Researchers Measured | Evidence Maturity |
|---|---|---|---|
| Innate immune defence | Human tissue, epithelial and neutrophil biology (observational) | Endogenous cathelicidin expression and its correlation with infection susceptibility | Descriptive human biology; not interventional dosing evidence |
| Acute bacterial challenge | In vitro isolates; animal infection models | MIC determination, time-kill kinetics, bacterial burden in tissue | Preclinical; human interventional data thin |
| Chronic wound repair | Animal wound models; ex vivo skin | Re-epithelialisation, immune cell recruitment to the wound bed, inflammatory signalling | Preclinical; concentration-dependent and biphasic in the reported models |
| Biofilm behaviour | In vitro biofilm systems | Adhesion, biofilm formation at sub-inhibitory concentrations, matrix penetration, biofilm density | In vitro; translation to animal or human systems not established here |
| Adjunct with conventional antibiotics | Checkerboard and synergy assays in vitro | Whether combination lowers the effective concentration of either agent | Early-stage in vitro; not a substitute for first-line treatment evidence |
| Antiviral activity | In vitro work with enveloped viruses | Viral membrane disruption and replication endpoints in culture | In vitro; concentration equivalents for living subjects not specified in the literature referenced here |
No column of this table carries a recommended amount, frequency, or duration, because the literature referenced on this page does not specify them for any of these contexts.
Frequently Raised Research Questions
Why Do Higher Concentrations Not Reliably Produce Greater Antimicrobial Effect?
Because the molecule has more than one described activity. The same amphipathic structure that disrupts anionic bacterial membranes interacts with host membranes as concentration rises, and the host-directed signalling component shifts from chemotaxis toward inflammatory amplification in preclinical systems. An assay that escalates concentration therefore changes more than one variable at once: antibacterial pressure, host cell viability, and inflammatory tone all move together. This is mechanistic reasoning drawn from general cationic peptide biology; the specific inversion point is model-dependent and is not specified in the literature referenced here.
How Do Storage Conditions Affect Peptide Integrity in Laboratory Work?
General peptide science describes hydrolysis, oxidation, aggregation, and surface adsorption as the principal loss pathways for peptides in aqueous solution, with temperature, light, and freeze-thaw cycling as accelerating factors. Because these losses are not necessarily visible, storage history is treated in well-designed studies as recorded metadata alongside the result. Compound-specific thresholds for LL-37 — how many hours outside refrigeration matter, how many days in solution remain acceptable — are not specified in the literature referenced on this page.
Why Do Some Antimicrobial Assays Show No Measurable LL-37 Activity?
A null result in a peptide assay has several plausible explanations that are not mutually exclusive: degraded or aggregated peptide, concentrations below the inhibitory band for the organism tested, media composition (serum proteins and divalent cations are described as antagonising cationic peptide activity in vitro), or an organism state such as biofilm encasement that limits access to the bacterial membrane. Distinguishing between these requires stability verification and appropriate controls rather than escalation, which is an experimental design observation rather than advice about what to administer.
What LL-37 Research Does and Does Not Establish
The honest summary is narrower than most write-ups suggest. LL-37 is not characterised in the literature as a substitute for conventional antibiotics in acute systemic infection, and the research contexts where it shows the most activity — localised models, biofilm systems, adjunct combinations in vitro — are also the contexts furthest from a validated human intervention. The "natural antibiotic" framing misrepresents the mechanism, because membrane disruption and FPR2-associated immune signalling are not the pathways that beta-lactams or fluoroquinolones use, and that difference cuts both ways: it is the reason the peptide is of research interest against isolates resistant to those drug classes, and it is also the reason findings from conventional antibiotic pharmacology do not transfer to it.
The concentration-response relationship is non-linear and context-dependent. A concentration that is uninformative in a planktonic assay may be relevant in a biofilm system, and a concentration that is antibacterial in culture may be cytotoxic in a wound model. Research designs calibrated to conventional antibiotic logic — escalate until an endpoint moves — frequently fail on this molecule not because the antimicrobial mechanism is absent, since membrane permeabilisation is well described, but because the design ignores the peptide's second, host-directed role. That is the gap the current evidence base leaves open, and it is the reason the field has not converged on a standard antimicrobial protocol for LL-37 in 2026.
FAQs
What is the best LL-37 dosage antimicrobial 2026 protocol guide?
There isn't one. No validated amount, frequency, duration, or administration route for antimicrobial use is specified in the literature referenced on this page, and LL-37 is supplied as research-grade material for laboratory use only, not for human consumption. Published antimicrobial work reports concentrations in assay systems (µg/mL or µM) in vitro and in animal models, which do not convert into a human schedule. Any page presenting a milligram-per-day chart for 2026 is presenting numbers the peer-reviewed record does not support.
Is there a standard LL-37 antimicrobial research protocol?
No single standardised method is treated as canonical across the field. Antimicrobial research designs for cathelicidin peptides vary by question: MIC determination and time-kill kinetics for planktonic bacteria, adhesion and matrix-penetration endpoints for biofilm systems, checkerboard assays for antibiotic synergy, and bacterial burden or re-epithelialisation endpoints in animal wound models. Media composition, peptide stability verification, and host-cell viability controls are recurring design variables. Because methods differ, results from one model are not directly comparable with another.
How is LL-37 studied for biofilm-associated bacteria?
In vitro biofilm systems are the dominant model. Endpoints described include inhibition of initial adhesion and biofilm formation at sub-inhibitory concentrations, penetration of the extracellular polysaccharide matrix, and viability or density of established biofilms. These are culture observations; the literature referenced here does not specify equivalents for living subjects, and translation from biofilm plates to animal or human infection is not established on this page.
How does LL-37 differ from conventional antibiotics mechanistically?
Conventional antibiotic classes inhibit defined enzymatic or ribosomal targets. LL-37 is described as acting physically on membranes — electrostatic attraction to anionic bacterial surfaces followed by bilayer permeabilisation — alongside host-directed signalling associated with FPR2. That difference in target class is the research rationale for studying it against isolates resistant to enzyme-targeting drugs. It is not evidence of clinical superiority, and bacterial countermeasures to cationic peptides, including surface charge modification and secreted proteases, are also described in the peptide literature.
Why is inflammation discussed in LL-37 research?
Because the peptide's host-directed activity is concentration-dependent. Preclinical work describes a shift from chemotactic and repair-associated signalling at lower concentrations toward inflammatory amplification and host-cell cytotoxicity as concentrations rise, which is why inflammatory readouts are measured alongside bacterial endpoints in wound and infection models. The specific concentration at which that shift occurs is model-dependent and is not specified in the literature referenced here.
How long does LL-37 in solution remain intact?
A compound-specific in-solution stability window is not specified in the literature referenced on this page. General peptide science describes hydrolysis, oxidation, aggregation, and surface adsorption as the main loss pathways in aqueous solution, accelerated by temperature, light, and freeze-thaw cycling, and notes that these losses can occur without visible change to the solution. Certificates of analysis and primary stability data are the appropriate sources for a defined window.
Can LL-37 replace antibiotics for active infections?
The research record does not support that framing. The contexts where activity is most consistently reported are localised in vitro and animal models, biofilm systems, and adjunct combinations tested in culture — not systemic infection in humans. Human interventional data on exogenously supplied LL-37 is thin, and no evidence on this page establishes it as an alternative to first-line treatment.
Does concentration change which LL-37 activity dominates?
In preclinical systems, yes. Lower assay concentrations are associated primarily with bacterial membrane disruption and chemotactic signalling; higher concentrations are associated with host-cell cytotoxicity and inflammatory cytokine signalling. This is described as a biphasic, non-linear relationship rather than a simple dose-effect line, which is why escalation in an assay changes several variables simultaneously. Exact numeric bands vary by organism, media, and model and are not specified here.
What is known about repeated or prolonged exposure?
Receptor-level adaptation to sustained ligand exposure is a general feature of G protein-coupled receptor signalling, and FPR2 is discussed in that context in the peptide literature. Whether prolonged exposure to exogenous LL-37 produces measurable desensitisation in a living system, over what interval, and whether any recovery period restores baseline responsiveness are questions the literature referenced on this page does not answer with specific figures. This is labelled mechanistic reasoning, not a compound-specific finding.
Does LL-37 show antiviral activity in research?
Antiviral activity against enveloped viruses is described for cathelicidin peptides in vitro, with membrane disruption as the proposed mechanism and viral replication endpoints in culture as the readout. These are laboratory observations. The concentrations involved, their relationship to the concentrations associated with host-cell effects, and any equivalent for a living subject are not specified in the literature referenced on this page.
What other peptides are studied alongside LL-37?
Research interest overlaps with other immune-modulating and repair-associated peptides, and combination work is generally early-stage in vitro. No combination method, sequence, or timing is specified in the literature referenced here, and none is described on this page. Related research-grade materials include Thymalin, MK 677, and KPV 5MG, each supplied for laboratory research.
All compounds discussed on this page are sold for research use only and are not for human consumption.
References
Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.
- Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
- Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
- Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
- Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
- Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
- Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
- LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
- Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA